Silo Pharma Enters Material Definitive Agreement
Ticker: SILO · Form: 8-K · Filed: Jun 27, 2024 · CIK: 1514183
| Field | Detail |
|---|---|
| Company | Silo Pharma, Inc. (SILO) |
| Form Type | 8-K |
| Filed Date | Jun 27, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, corporate-actions
Related Tickers: SILO
TL;DR
Silo Pharma (SILO) signed a big deal. Details to follow.
AI Summary
Silo Pharma, Inc. announced on June 26, 2024, that it entered into a material definitive agreement. The company, formerly known as Uppercut Brands, Inc., Point Capital, Inc., and Gold Swap Inc., is incorporated in Nevada and headquartered in Sarasota, Florida.
Why It Matters
This filing indicates a significant business development for Silo Pharma, Inc., potentially impacting its future operations and financial standing.
Risk Assessment
Risk Level: medium — Entering into a material definitive agreement can introduce new risks and opportunities, the specifics of which are not yet detailed in this initial filing.
Key Players & Entities
- Silo Pharma, Inc. (company) — Registrant
- June 26, 2024 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- Sarasota, FL (location) — Principal business address
- Uppercut Brands, Inc. (company) — Former company name
- Point Capital, Inc. (company) — Former company name
- Gold Swap Inc (company) — Former company name
FAQ
What is the nature of the material definitive agreement entered into by Silo Pharma, Inc.?
The filing states that Silo Pharma, Inc. entered into a material definitive agreement on June 26, 2024, but the specific details of this agreement are not provided in this initial 8-K filing.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on June 26, 2024.
In which state is Silo Pharma, Inc. incorporated?
Silo Pharma, Inc. is incorporated in Nevada.
What is the principal business address of Silo Pharma, Inc.?
The principal business address of Silo Pharma, Inc. is 677 N. Washington Boulevard, Sarasota, FL 34236.
What were some of Silo Pharma, Inc.'s former company names?
Silo Pharma, Inc. was formerly known as Uppercut Brands, Inc., Point Capital, Inc., and Gold Swap Inc.
Filing Stats: 476 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-06-27 16:23:20
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share SILO The Nasdaq Stock Mar
Filing Documents
- ea0208662-8k_silo.htm (8-K) — 24KB
- ea020866201ex10-1_silo.htm (EX-10.1) — 13KB
- 0001213900-24-056678.txt ( ) — 207KB
- silo-20240626.xsd (EX-101.SCH) — 3KB
- silo-20240626_lab.xml (EX-101.LAB) — 33KB
- silo-20240626_pre.xml (EX-101.PRE) — 22KB
- ea0208662-8k_silo_htm.xml (XML) — 3KB
01. Entry into a Material Definitive
Item 1.01. Entry into a Material Definitive Agreement. On June 26, 2024, our wholly-owned subsidiary, Silo Pharma, Inc., a Florida corporation, entered into a Fourth Amendment to Master License Agreement (the "Fourth Amendment") with the University of Maryland, Baltimore, pursuant to which the parties agreed to an amended and restated schedule of diligence milestones for the Master License Agreement. The foregoing description of the Fourth Amendment does not purport to be complete and is qualified in its entirety by reference to the Fourth Amendment, which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit Description 10.1 Fourth Amendment to Master License Agreement 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: June 27, 2024 SILO PHARMA INC. /s/ Eric Weisblum Eric Weisblum Chief Executive Officer 2